{"id":955268,"date":"2026-04-28T07:34:48","date_gmt":"2026-04-28T11:34:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-nine-upcoming-presentations-at-the-european-society-of-cardiology-heart-failure-2026-congress\/"},"modified":"2026-04-28T07:34:48","modified_gmt":"2026-04-28T11:34:48","slug":"cytokinetics-announces-nine-upcoming-presentations-at-the-european-society-of-cardiology-heart-failure-2026-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-nine-upcoming-presentations-at-the-european-society-of-cardiology-heart-failure-2026-congress\/","title":{"rendered":"Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9\u201312, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO\u00ae<\/sup> (aficamten).<\/em> Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.<\/p>\n

\n Late Breaking Science Oral Presentation<\/strong>\n <\/p>\n

\n Title<\/strong>: Dose-dependent effects of aficamten<\/em> compared with metoprolol in obstructive HCM: the MAPLE-HCM study<\/a>
Presenter<\/strong>: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor at Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
Date: <\/strong>May 11, 2026
Session Title: <\/strong>Advances in Cardiomyopathies
Session Time<\/strong>: 3:30 PM \u2013 4:30 PM CEST
Presentation Time: <\/strong>4:06 PM \u2013 4:18 PM CEST
Location: <\/strong>Room 3<\/p>\n

\n Rapid Fire Presentations<\/strong>\n <\/p>\n

\n Title<\/strong>: Favorable Effect of Aficamten<\/em> on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial<\/a>
Presenter<\/strong>: Yasuhiro Hamatani, M.D., Ph.D., Postdoctoral Fellow, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA
Date: <\/strong>May 9, 2026
Session Title: <\/strong>Advanced Phenotyping and Risk Stratification in Cardiomyopathies and Myocarditis
Session Time<\/strong>: 3:30 PM \u2013 4:30 PM CEST
Presentation Time: <\/strong>3:47 PM \u2013 3:55 PM CEST
Location: <\/strong>Agora 2<\/p>\n

\n
\n Title<\/u>
\n <\/strong>
\n : <\/u>
\n Effect of Aficamten<\/em> Compared with Metoprolol in Women Versus Men: Analysis of MAPLE-HCM<\/a>
\n
\n Presenter:<\/strong> Xiaowen Wang, MD, MPH, Associate Director, Cardiac Imaging Core Lab, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA
Date: <\/strong>May 10, 2026
Session Title:<\/strong> Novel and Targeted Therapies: Precision Pharmacology in Heart Failure
Session Time<\/strong>: 2:30 PM \u2013 3:15 PM CEST
Presentation Time:<\/strong>\u00a0<\/strong>2:57 PM \u2013 3:06 PM CEST
Location: <\/strong>Agora 2<\/p>\n

In addition to the rapid fire presentations related to MYQORZO\u00ae<\/sup> (aficamten<\/em>), one presentation will offer further insights into the treatment effect of omecamtiv mecarbil<\/em> in heart failure with reduced ejection fraction (HFrEF).<\/p>\n

\n Title: <\/strong>
\n The Influence of QRS Duration and Resynchronization Status on the Efficacy and Safety of Omecamtiv Mecarbil<\/em> in Heart Failure with Reduced Ejection Fraction: The GALACTIC-HF Trial<\/a>
\n
\n Presenter: <\/strong>Mih\u00e1ly Ruppert, MD, PhD, Researh Fellow, Brigham and Women’s Hospital, Boston, MA, USA
Date: <\/strong>May 10, 2026
Session Title:<\/strong> Novel and Targeted Therapies: Precision Pharmacology in Heart Failure
Session Time<\/strong>: 2:30 PM \u2013 3:15 PM CEST
Presentation Time:<\/strong>\u00a0<\/strong>2:39 PM \u2013 2:48 PM CEST
Location: <\/strong>Agora 2<\/p>\n

\n Moderated Posters<\/strong>\n <\/p>\n

\n Title: <\/strong>
\n No Increase in Arrhythmia Burden Following Aficamten<\/em> Treatment in Obstructive Hypertrophic Cardiomyopathy: Extended Ambulatory Electrocardiogram Analysis From FOREST-HCM<\/a>
\n
\n Presenter: <\/strong>Ethan J. Rowin, M.D., Associate Professor of Medicine at UMass Chan-Lahey, UMass Chan Medical School, Lahey Hospital & Medical Center, Burlington, MA
Date: <\/strong>May 11, 2026
Session Title:<\/strong> Hypertrophic Obstructive Cardiomyopathy: Treatment, Monitoring, and Outcomes
Session Time<\/strong>: 1:30 PM \u2013 2:15 PM CEST
Location: <\/strong>Moderated ePosters 3<\/p>\n

\n Title: <\/strong>
\n Clinical and Economic Burden in NYHA Class I Versus II-IV Hypertrophic Cardiomyopathy: Real-World Survey Data From the United States of America<\/a>
\n
\n Presenter: <\/strong>Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics
Date: <\/strong>May 10, 2026
Session Title:<\/strong> Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy
Session Time<\/strong>: 10:30 AM \u2013 11:15 AM CEST
Location: <\/strong>Moderated ePosters 3<\/p>\n

\n Title:<\/strong>
\n Impact of Guideline-Directed Medical Therapies on Clinical and Economic Outcomes in Nonobstructive Hypertrophic Cardiomyopathy: Analysis of Data from a Multinational Cross-Sectional Survey<\/a>
\n
\n Presenter: <\/strong>Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics, South San Francisco, CA
Date: <\/strong>May 10, 2026
Session Title:<\/strong> Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy
Session Time<\/strong>: 10:30 AM \u2013 11:15 AM CEST
Location: Moderated ePosters 3<\/strong><\/p>\n

\n ePoster Presentations<\/strong>\n <\/p>\n

\n Title: <\/strong>
\n Impact of Hypertrophic Cardiomyopathy on Work Productivity and Activity Impairment in Patients with HCM: Analysis of a Real-World Cross-Sectional Survey<\/a>
\n
\n Presenter: <\/strong>Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics, South San Francisco, CA
Date: <\/strong>May 9, 2026
Session Title: <\/strong>ePosters in myocardial disease – hypertrophic cardiomyopathy (2)
Session Time: <\/strong>8:30 AM \u2013 5:30 PM CEST
Presentation Time: <\/strong>8:30 AM \u2013 9:30 AM CEST
Location: <\/strong>ePosters screen 22<\/p>\n

\n Title: <\/strong>
\n Phenotypic Distribution and Clinical Burden of Pediatric Hypertrophic Cardiomyopathy: Insights From a Longitudinal US Claims Database<\/a>
\n
\n Presenter: <\/strong>Jennifer Conway, MD, FRCPC, MSc, Professor of Pediatrics, Director of the Heart Function and Cardiomyopathy Program, Stollery Children\u2019s Hospital, Edmonton, Canada
Date: <\/strong>May 10, 2026
Session Title<\/strong>: ePosters in myocardial disease – hypertrophic cardiomyopathy (2)
Session Time:<\/strong> 8:30 AM \u2013 5:30 PM CEST
Presentation Time:<\/strong> 4:30 PM \u2013 5:30 PM CEST
Location: <\/strong>ePosters screen 22<\/p>\n

\n About MYQORZO<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (<\/strong>
\n
\n aficamten<\/em>
\n <\/strong>
\n )<\/strong>\n <\/p>\n

MYQORZO\u00ae <\/sup>(aficamten<\/em>) is a cardiac myosin inhibitor approved in the U.S., China and European Union for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.1<\/sup><\/p>\n

\n Aficamten <\/em>is also under clinical investigation in ACACIA-HCM, a Phase 3 trial in patients with non-obstructive HCM (nHCM) and CEDAR-HCM, in a pediatric population with oHCM. Aficamten<\/em> has not been deemed safe or effective for use in either of these patient populations. In addition, aficamten<\/em> is being studied in FOREST-HCM, an open-label extension clinical study.<\/p>\n

\n INDICATIONS AND USAGE <\/strong>\n <\/p>\n

MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n\n\n\n
\n WARNING: RISK OF HEART FAILURE<\/strong><\/p>\n

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.<\/strong><\/p>\n

Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and \u226540%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction<\/strong>
\n
\n . <\/em>
\n <\/strong><\/p>\n

Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.<\/strong>\n <\/td>\n<\/tr>\n

\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n CONTRAINDICATIONS<\/strong>\n <\/p>\n

MYQORZO is contraindicated with concomitant use of rifampin.<\/p>\n

\n WARNING AND PRECAUTIONS<\/strong>\n <\/p>\n

\n Heart Failure<\/strong>\n <\/p>\n

MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.
Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.<\/p>\n

Assess patients\u2019 clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.<\/p>\n

Initiation of MYQORZO in patients with LVEF <55% is not recommended.<\/p>\n

\n MYQORZO REMS Program<\/strong>\n <\/p>\n

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.<\/p>\n

Notable requirements of the MYQORZO REMS Program include:<\/p>\n